



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.)

Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840

11th November, 2020

Online Filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Limited,
Rotunda Building,
P.J. Tower, Dalal Street, Fort
MUMBAI - 400001

BSE CODE: 524606

Sub: Submission of Unaudited Standalone Financial Results along with the Limited Review report for the quarter/half year ended 30th September, 2020 as per regulation 33(3) (d) of SEBI (LODR) Regulations, 2015.

Dear Sir,

This is in continuation of our Notice dated 04th November, 2020 regarding intimation of Board meeting to be held on Wednesday, 11th November 2020 for Consideration of the Unaudited Standalone Financial Results for the quarter/half year ended 30th September, 2020.

Further pursuant to Regulation 33(3) (d) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Unaudited Standalone Financial Results along with the Limited Review report thereon by statutory Auditors for the quarter/half year ended 30th September, 2020 in the PDF format which was considered and approved by the Audit Committee and the board of directors of the company at their respective meeting held on Wednesday, 11th November 2020.

We are also in the process to file the aforesaid financial results in the XBRL form within the stipulated time of 24 Hours from the conclusion of the board meeting and also being hosted at the website of the company www.beryl drugs.com


The Unaudited Standalone Financial Results will also be published in widely circulated English Newspaper and Hindi in the prescribed format for the purpose.

You are requested to please take on record the aforesaid Financial Results along with the Auditor's Report for your record and reference.

Thanking you.
Yours faithfully

For Beryl Drugs Limited

Sudhir Sethi
Chairman & Director
DIN: 00090172





BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
Tel./ Fax 0731-2517677
E-mail : beryldrugs25@yahoo.com

ANNEXURE I

Part I Submission of Unaudited Financial Result by Companies Other than Banks


Statement of standalone Unaudited Result for the Quarter/ year ended 30/09/2020 (Rs in 000)

Particulars	Quarter ended			Half year ended		Year ended
	3 months ended (30-09-2020)	Preceding 3 months ended (30-06-2020)	Corresponding 3 months ended in the previous year (30-09-2019)	Year to date figures for current period ended (30-09-2020)	Year to date figures for previous period ended (30-09-2019)	Previous year ended (31-03-2020)
(Refer Notes Below)	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue From Operations						
Net sales or Revenue from Operations	32691.000	26965.000	32723.000	59656.000	75026.000	128151.000
Other operating revenues	5381.000	51.000	686.000	5432.000	713.000	2331.000
Total Revenue from operations (net)	38072.000	27016.000	33409.000	65088.000	75739.000	130482.000
2 Expenses						
(a) Cost of materials consumed	18836.000	16399.000	16685.000	35235.000	37035.000	66779.000
(b) Purchases of stock-in-trade	0.000	0.000	0.000	0.000	0.000	0.000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-1270.000	-2437.000	-1474.000	-3707.000	-514.000	-700.000
(d) Employee benefit expense	2637.000	2514.000	2216.000	5151.000	4194.000	9653.000
(e) Finance costs	938.000	1381.000	235.000	2319.000	1221.000	3210.000
(f) Depreciation and amortisation expense	3459.000	3459.000	1045.000	6918.000	2090.000	6594.000
(g) Other Expenses	8719.000	7441.000	12393.000	16160.000	25553.000	43367.000
Total expenses	33319.000	28757.000	31100.000	62076.000	69579.000	128903.000
Profit (loss) from operations before exceptional and extraordinary items and tax	4753.000	-1741.000	2309.000	3011.000	6160.000	1579.000
4 Exceptional Items	0.000	0.000	0.000	0.000	0.000	0.000
5 Profit (loss) before tax	4753.000	-1741.000	2309.000	3011.000	6160.000	1579.000
6 Tax Expense						
Current tax	460.000	0.000	700.000	460.000	1300.000	-355.000
Deferred tax	-594.000	219.000	-126.000	-375.000	-301.000	1455.000
Total Tax Expenses	-134.000	219.000	574.000	85.000	999.000	1100.000
7 Net Profit (loss) for the period from continuing operations	4887.000	-1960.000	1735.000	2926.000	5161.000	479.000
8 Net Profit (loss) from discontinuing operations before tax	0.000	0.000	0.000	0.000	0.000	0.000
9 Tax Expense of discontinuing operations	0.000	0.000	0.000	0.000	0.000	0.000
10 Net Profit (loss) from discontinuing operations after tax	0.000	0.000	0.000	0.000	0.000	0.000
11 Net Profit (loss) for the Period	4887.000	-1960.000	1735.000	2926.000	5161.000	479.000
12 Other comprehensive income	1515.000	-634.000	-7.000	881.000	-89.000	494.000
Total Comprehensive Income	6402.000	-2594.000	1728.000	3807.000	5072.000	973.000
14 Details of equity share capital						
Paid-up equity share capital	50717.000	50717.000	50717.000	50717.000	50717.000	50717.000
Face value of equity share capital	10.000	10.000	10.000	10.000	10.000	10.000
15 Earnings per share						
i Basic earnings per share before extraordinary items	0.96	-0.39	0.34	0.58	1.02	0.09
ii Diluted earnings per share before extraordinary items	0.96	-0.39	0.34	0.58	1.02	0.09

Notes:

- The above financial results have been prepared in accordance with the recognition and measurement principles stated therein prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- The above results for the quarter ended 30th September 2020 which have been subjected to Limited Review by Statutory Auditors of the Company were reviewed and recommended by the Audit Committee and subsequently by the Board of Directors at its meeting held on 11th Nov.2020 in terms of regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015.
- The Income from Operations is from one segment namely "Pharmaceutical Industry".
- Other income includes Profit on sale of non-current Investments amounting to Rs.45.19 Lacs.
- The figures for the previous periods have been regrouped, wherever necessary.
- Depreciation is provided on Written down value method on the estimated remaining useful lives of the assets.
- Earnings per Share amount is Shown in Rupees.

Place : Indore
Date : 11.11.2020



For and behalf of the Board


Sanjay Sethi
Managing Director

BERYL DRUGS LIMITED
133, KANCHAN BAGH
INDORE (M.P.)
CASH FLOW STATEMENT
FOR THE HALF YEAR ENDED 30th SEP, 2020

	(Rs. In 000)	
	For the Half year ended 30th Sep 2020	For the Half year ended 30th Sep 2019
A: CASH FLOW FROM OPERATING ACTIVITIES		
Net Loss Before Tax as per Statement of Profit and Loss	3011	6,160
Adjusted for:		
Depreciation / Amortisation Expense	6918	2,090
Rental Income	(626)	(637)
Interest Income	(89)	(77)
Finance costs	2319	1,221
Profit on sale of Investment	(4519)	0
Operating Profit before Working Capital Changes	7014	8,757
Adjusted for:		
Inventories		
Increase/ (Decrease) in Trade Payables	(5838)	(1,178)
(Increase) / Decrease in Trade Receivables	(4765)	(569)
Other Current Assets	(402)	1,814
Other Financial Assets	8862	(1,220)
Other Financial Liabilities	(5050)	(33)
Other Current Liabilities	(1536)	0
Provisions	(33)	(2,752)
Cash Generated from Operations	(71)	128
Taxes Paid (Net)	(1819)	4947
Net Cash flow from Operating Activities	(1881)	4,626
B: CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of tangible and intangible assets	(19)	(377)
Proceeds from disposal of tangible and intangible assets	0	0
Capital Work in Progress	(4191)	(6777)
Capital Advances and Others	(4124)	(446)
Proceeds from Sale of Investments	9716	0
Interest Income	89	77
Rental Income	625	636
Net Cash flow (Used in) Investing Activities	2096	(6887)
C: CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Long Term Borrowings	7600	0
Repayment of Long Term Borrowings	(2526)	(1558)
Short Term Borrowings	(1096)	6858
Finance Costs	(2319)	(1221)
Net Cash flow from/(Used in) Financing Activities	1659	4079
Net (Decrease) in Cash and Cash Equivalents	1874	1818
Opening Balance of Cash and Cash Equivalents	3963	998
Closing Balance of Cash and Cash Equivalents	5837	2816

1. The above Cash Flow Statement has been prepared under the Indirect method as set out on Ind AS 7 "Statement of Cash Flows"
2. Figures for the Previous year have been re-arranged and re-grouped wherever necessary to confirm with the current year classification.
3. Figures in the brackets represent Outflows.

For Beryl Drugs Limited



PLACE: INDORE
Date: 11.11.2020

BERYL DRUGS LIMITED

1 33, KANCHAN BAGH (INDORE (M.P.))

STATEMENT OF ASSETS AND LIABILITIES AS AT 30th SEPTEMBER 2020

CIN: L02423MP1993PLC007840


(Rs. In 000)

PARTICULARS	As at 30th September 2020	As at 31st March 2020
A. ASSETS		
Non-current assets		
Property plant and equipment	76436	84698
Capital Work-in-Progress	4191	0
Investment Property	2627	1264
Other Intangible assets	71	71
Financial Assets		
Investments	1666	5617
Trade Receivables	0	0
Loans	0	0
Other Financial Assets	0	0
Deferred Tax Assets (Net)	0	0
Other Non-current assets	6455	2330
Total Non-Current assets	91446	93981
Current Assets		
Inventories		
Financial Assets	17411	11573
Investments	0	0
Trade receivables	34944	34541
Cash and cash equivalents	5838	3963
Loans	0	0
Other Financial Assets	7002	1952
Current Tax Asset (Net)	676	615
Other Current Assets	13630	22492
Total Current assets	79501	75137
Total Assets	170947	169118
E. EQUITY AND LIABILITIES		
Equity		
Equity Share capital	50937	50937
Other Equity	29125	25318
Total Equity	80062	76255
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	28101	23123
Provisions	3150	2657
Deferred Tax Liabilities (Net)	430	806
Other Non-Current Liabilities	0	0
Total non-current liabilities	31681	26586
Current liabilities		
Financial Liabilities		
Borrowings	22832	23929
Trade payables	13256	18021
Other Financial Liabilities	18487	19927
Other Current liabilities	4562	4135
Provisions	67	265
Total current liabilities	59204	66277
Total Liabilities	90885	92863
Total Equity and Liabilities	170947	169118

Date: 11/11/2020
Place: Indore

For Beryl Drugs Limited

Sanjay Sethi
SANJAY SETHI
(MANAGING DIRECTOR)
DIN:00090277



PRATEEK JAIN & CO.


CHARTERED ACCOUNTANTS

212, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,

INDORE (M.P.) 452001

PH. 9827013187, 731-2520955

E-MAIL: caprateekjain@gmail.com



Independent Auditor's Review Report on the Quarterly unaudited and year to date Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, read with SEBI Circular No. CIRJCFD/CMDI/44/2019 dated March 29, 2019

To,
The Board of Directors
Beryl Drugs Limited
133, Kanchan Bagh,
Indore (M.P.) - 452001

We have reviewed the accompanying statement of unaudited financial results of **BERYL DRUGS LIMITED** ("the Company") for the quarter ended **30th September, 2020** and year to date from April 1, 2020 to September 30, 2020 attached herewith, being submitted by the Company pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by Independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 11th November, 2020
Place: Indore



FOR PRATEEK JAIN AND CO.
CHARTERED ACCOUNTANTS
FRN-009494C

Prateek Jain

PRATEEK JAIN
PROPRIETOR
M. No. 079214

UDIN: 20079214AAAABR9965